Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To study the efficacy of iv AZD7009 in all treatment groups versus placebo, in conversion of AF. The primary outcome variable for the evaluation of this objective is: -the proportion of patients that have converted from AF within 90 min from start of infusion. Conversion has occurred if SR (and/or AV junctional rhythm) is maintained for at least 2 min A secondary outcome variable evaluating the primary objective is: -the time to conversion from AF from start of infusion up to 90 min
Critère d'inclusion
- Atrial fibrillation (AF)